Literature DB >> 8396143

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

R Göke1, H C Fehmann, T Linn, H Schmidt, M Krause, J Eng, B Göke.   

Abstract

Exendin-4 purified from Heloderma suspectum venom shows structural relationship to the important incretin hormone glucagon-like peptide 1-(7-36)-amide (GLP-1). We demonstrate that exendin-4 and truncated exendin-(9-39)-amide specifically interact with the GLP-1 receptor on insulinoma-derived cells and on lung membranes. Exendin-4 displaced 125I-GLP-1, and unlabeled GLP-1 displaced 125I-exendin-4 from the binding site at rat insulinoma-derived RINm5F cells. Exendin-4 had, like GLP-1, a pronounced effect on intracellular cAMP generation, which was reduced by exendin-(9-39)-amide. When combined, GLP-1 and exendin-4 showed additive action on cAMP. They each competed with the radio-labeled version of the other peptide in cross-linking experiments. The apparent molecular mass of the respective ligand-binding protein complex was 63,000 Da. Exendin-(9-39)-amide abolished the cross-linking of both peptides. Exendin-4, like GLP-1, stimulated dose dependently the glucose-induced insulin secretion in isolated rat islets, and, in mouse insulinoma beta TC-1 cells, both peptides stimulated the proinsulin gene expression at the level of transcription. Exendin-(9-39)-amide reduced these effects. In conclusion, exendin-4 is an agonist and exendin-(9-39)-amide is a specific GLP-1 receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396143

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  206 in total

Review 1.  Insulinotropic toxins as molecular probes for analysis of glucagon-likepeptide-1 receptor-mediated signal transduction in pancreatic beta-cells.

Authors:  G G Holz; C A Leech; J F Habener
Journal:  Biochimie       Date:  2000 Sep-Oct       Impact factor: 4.079

2.  Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function.

Authors:  Cassandra Koole; Denise Wootten; John Simms; Emilia E Savage; Laurence J Miller; Arthur Christopoulos; Patrick M Sexton
Journal:  J Biol Chem       Date:  2011-12-06       Impact factor: 5.157

3.  Facilitation of ß-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac.

Authors:  Colin A Leech; Igor Dzhura; Oleg G Chepurny; Frank Schwede; Hans-G Genieser; George G Holz
Journal:  Islets       Date:  2010 Mar-Apr       Impact factor: 2.694

Review 4.  The structure and function of the glucagon-like peptide-1 receptor and its ligands.

Authors:  Dan Donnelly
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

5.  Genetically Encoded Cholesterol-Modified Polypeptides.

Authors:  Davoud Mozhdehi; Kelli M Luginbuhl; Michael Dzuricky; Simone A Costa; Sinan Xiong; Fred C Huang; Mae M Lewis; Stephanie R Zelenetz; Christian D Colby; Ashutosh Chilkoti
Journal:  J Am Chem Soc       Date:  2019-01-04       Impact factor: 15.419

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 7.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

8.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

9.  Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury.

Authors:  Nigel H Greig; David Tweedie; Lital Rachmany; Yazhou Li; Vardit Rubovitch; Shaul Schreiber; Yung-Hsiao Chiang; Barry J Hoffer; Jonathan Miller; Debomoy K Lahiri; Kumar Sambamurti; Robert E Becker; Chaim G Pick
Journal:  Alzheimers Dement       Date:  2014-02       Impact factor: 21.566

10.  Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.

Authors:  He Meng; Subrahmanian Tarakkad Krishnaji; Martin Beinborn; Krishna Kumar
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.